Profil Institute for Clinical Research

En la Communidad

dan — Thu, 16 May 2013 21:30:50 +0000

The post En la Communidad appeared first on Profil Institute for Clinical Research.

Apertura de Nuevas Instalaciones

dan — Thu, 16 May 2013 21:27:00 +0000

The post Apertura de Nuevas Instalaciones appeared first on Profil Institute for Clinical Research.

Ingresar a un Estudio

dan — Thu, 16 May 2013 21:18:28 +0000

The post Ingresar a un Estudio appeared first on Profil Institute for Clinical Research.

Profil Institute Assembles Team of 80 Cyclists for American Diabetes Association’s Tour de Cure in San Diego

abby — Wed, 17 Apr 2013 19:51:00 +0000

Profil Institute’s 9th Year as a Corporate Sponsor of ADA’s Fund-raising Event

SAN DIEGO, April 17, 2013 /PRNewswire/ – Profil^® Institute for Clinical Research, Inc., focused on providing science-driven early phase diabetes, obesity and cardiometabolic clinical research services, announced today its 9^th year as a corporate sponsor of the American Diabetes Association’s Tour de Cure and a 100% increase of participants fund-raising for this event as members of the Profil Peddlers Corporate Team.

Profil Peddler participants are cyclists representing all levels of athletic prowess, many of whom are affected by diabetes or supporting others with diabetes and many of whom are employees of the team organizer Profil Institute for Clinical Research, headquartered in Chula Vista. What they have in common is a goal of supporting the American Diabetes Association and making a difference in the lives of diabetic patients and their families.

The Profil Peddler team has doubled its number of team participants from nearly 40 in 2012 to a team of 80 cyclists this year that have already raised over $20,000 for this year’s event and expect to reach over $22,000 by this weekend.

“Profil Institute is an ardent supporter of the American Diabetes Association and other advocacy groups with a similar mission of advancing research to eradicate diabetes and improving the lives of people with this and related metabolic disorders,” said Claus Hakenesch, Profil Institute’s CFO, Tour de Cure Committee member, and a Profil Peddler. “The Tour de Cure is our opportunity as a company to sponsor and volunteer for a meaningful and impactful event in our community while cycling and enjoying camaraderie with the very people for whom our clinical research is impacting.”

This year’s Tour de Cure will take place Saturday, April 20 beginning at Torrey Pines High School. The Tour de Cure, a fund-raising event with cyclists participating in routes of 10 to 100 miles, attracts more than 55,000 cyclists in 80 events nationwide and raised more than $18 million last year. Funds raised are used to support the mission of the American Diabetes Association to prevent and cure diabetes and to improve the lives of all people affected by the disease.

“The Profil Peddler team includes people with and without diabetes that are role models inspiring people to live healthy, physically active lives to help manage or prevent diabetes,” said Carmen Jany-O., Profil Peddler team captain and Profil Peddler herself since 2010. “From former couch potatoes to semi-pro cyclists, Profil Peddlers are a team of people from all walks of life passionate about raising funds, while have a good time doing it, for this amazing event.”

For more information about San Diego’s Tour de Cure to take place on Saturday, April 20, 2013, visit the website: http://main.diabetes.org/goto/profilpeddlers.

About Profil^® Institute for Clinical Research, Inc.

Profil Institute is internationally renowned as a Center of Excellence for early phase clinical research of drugs and devices for diabetes, obesity and cardiometabolic diseases. The company’s scientific expertise, advanced metabolic clinical research methodologies, and automated glucose clamp technology enable Profil Institute to execute studies of far more complexity and have led Profil Institute to be the most highly regarded clinical research institute for early phase diabetes drug studies. Profil Institute has been involved with every clinically promising drug class in diabetes and in more than 175 clinical studies since the company’s inception in 2004. For more information visit www.profilinstitute.com.

For further information, please contact:

Abby Devine
Associate Director of Corporate Communications
abby.devine@profilinstitute.com
858-663-6148

The post Profil Institute Assembles Team of 80 Cyclists for American Diabetes Association’s Tour de Cure in San Diego appeared first on Profil Institute for Clinical Research.

Profil Institute and Mercodia Announce Partnership Offering Insulin and Metabolism ELISA Assays to Enhance Diabetes and Obesity Clinical Trials

abby — Wed, 10 Apr 2013 13:00:49 +0000

SAN DIEGO and UPPSALA, SWEDEN, April 10, 2013 /PRNEWSWIRE/ – Profil^® Institute for Clinical Research, Inc., a clinical research institute optimizing early phase diabetes, obesity and cardiometabolic drug development, and Mercodia AB, an industry-leading developer of immunoassays for metabolic clinical and research applications, jointly announced today a strategic alliance to include Mercodia’s enzyme-linked immnosorbent assays (ELISA) as a component of Profil Institute’s early phase clinical services.

Both Profil Institute and Mercodia are widely recognized for their expertise in diabetes, obesity and cardiometabolic research. Profil Institute is a center of excellence for early phase metabolic clinical research and is renowned for its expertise in proof of mechanism methods, including first-in-patient and automated glucose clamp studies, and its large patient recruitment database. Mercodia is globally recognized for its robust ELISA assay development for metabolic clinical research and to study the pharmacokinetics of insulin and metabolic peptides. Mercodia’s assays will now be offered to Profil Institute’s clients as a component of the clinical trial process.

“With the addition of Mercodia’s robust ELISA assays, we further enhance our wide scope of clinical research services, generating unprecedented investigative standards for early phase diabetes and obesity drug development,” said Dr. Marcus Hompesch, Profil Institute CEO. “Our scientific understanding of diabetes and of the pharmacokinetic and pharmacodynamic effects of insulin, as well as our expertise working with all diabetes drug classes, enables us to provide highly conclusive data so that our clients can make the best decisions, as early as possible, about the further development of their drug candidates.”

“We are very pleased to partner with Profil Institute and therefore combine our disease area expertise for a powerful outcome in the precision of clinical research data,” said Mona Österberg, CEO of Mercodia AB. “Together we will deliver greater scientific insight to Profil Institute’s customers enhancing their overall metabolic drug development program at the earliest stage of clinical research in humans.”

About Mercodia AB

Mercodia AB is a Swedish biotech company focusing on the development of highly reproducible and specific ELISA assays within the field of metabolic disorders. Mercodia is a world-leading supplier to all major international markets and provides a professional scientific support system to develop novel applications for existing products and unique diagnostics for emerging markets. The facilities include a GLP-compliant laboratory and a customized assay development core managed by our extensive quality system and ISO 13485 for manufacturing medical devices. For more information visit www.mercodia.com.

About Profil^® Institute for Clinical Research, Inc.

For further information, please contact:

Abby Devine
Associate Director of Corporate Communications
abby.devine@profilinstitute.com
858-663-6148

The post Profil Institute and Mercodia Announce Partnership Offering Insulin and Metabolism ELISA Assays to Enhance Diabetes and Obesity Clinical Trials appeared first on Profil Institute for Clinical Research.